Clinical Report: Reinforcing the OD’s Importance

Overview

This report discusses the implications of GLP-1 agonists on diabetic retinopathy (DR) and the critical role of optometrists in monitoring this condition. With a significant portion of the population using these medications, understanding their effects on eye health is essential for patient care.

Background

Type 2 diabetes and obesity are prevalent health issues in the U.S., with GLP-1 agonists emerging as effective treatments. As these medications gain popularity, it is crucial for optometrists to be aware of their potential impact on diabetic retinopathy, a serious complication of diabetes. This awareness reinforces the optometrist's role in the healthcare team, particularly in monitoring and managing DR.

Data Highlights

Approximately 8% to 10% of Americans are currently using GLP-1 agonists, with 30% to 35% expressing interest in these treatments.

Key Findings

• GLP-1 agonists are effective in managing type 2 diabetes and obesity.
• There is a potential link between GLP-1 agonists and worsening diabetic retinopathy.
• Optometrists play a vital role in monitoring diabetic retinopathy progression.
• Electroretinography (ERG) can aid in early detection of DR in patients using GLP-1 agonists.
• Regular dilated eye exams are essential for patients on GLP-1 therapy.

Clinical Implications

Optometrists should consider informing local healthcare providers about the association between GLP-1 agonists and diabetic retinopathy. Enhanced monitoring strategies for patients using these medications may improve patient outcomes and facilitate better management of DR.

Conclusion

The increasing use of GLP-1 agonists necessitates a proactive approach from optometrists in monitoring diabetic retinopathy. This reinforces the importance of their role in the broader healthcare team.

References

1. Optometric Management, 2025 -- Viewpoint: A fitting guide for contact lenses
2. Optometric Management, 2015 -- viewpoint
3. Optometric Management, 2025 -- Reemphasizing the ODs Crucial Role in Cataract and Glaucoma Care Recommendations
4. Optometric Management, 2007 -- Viewpoint
5. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026 - PMC
6. Association of glucagon-like peptide-1 (GLP-1) receptor agonists and diabetic retinopathy (DR) – a systematic review and meta-analysis - PMC
7. The use of semaglutide medicines and risk of non-arteritic anterior ischemic optic neuropathy (NAION)
8. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026 - PMC
9. Association of glucagon-like peptide-1 (GLP-1) receptor agonists and diabetic retinopathy (DR) – a systematic review and meta-analysis - PMC
10. The use of semaglutide medicines and risk of non-arteritic anterior ischemic optic neuropathy (NAION)